Stem Cell to Cure Diseases

Kadimastem is a leading regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders.

The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin secreting beta cells as well as a range of neural cells (Oligodendrocytes, Astrocytes, Motoneurons).  

Kadimastem’s lead program for diabetes mellitus is based on stem cells-derived insulin secreting beta cells designed to be implanted in diabetic patients, enabling autonomous control of blood glucose levels and secretion of insulin and glucagon.

In addition, Kadimastem is partnering with pharmaceutical companies interested to screen potential drug compounds on its stem-cell derived cells. The company’s technology is capable of screening compounds automatically and quantifying the readouts using a cell-based High Content Screening (HCS) system.